Johnson & Johnson's Second Interim Analysis Of Phase 3 Cartitude-4 Study Of Carvykti Vs. Standard Therapies For Relapsed Or Lenalidomide-Refractory Multiple Myeloma, Show Statistically Significant, Clinically Meaningful Improvement In Overall Survival
Portfolio Pulse from Benzinga Newsdesk
Johnson & Johnson's second interim analysis of the Phase 3 Cartitude-4 study of Carvykti versus standard therapies for relapsed or lenalidomide-refractory multiple myeloma shows statistically significant and clinically meaningful improvement in overall survival.
July 02, 2024 | 11:37 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Johnson & Johnson's Phase 3 Cartitude-4 study of Carvykti shows significant improvement in overall survival for relapsed or lenalidomide-refractory multiple myeloma patients.
The positive results from the Phase 3 Cartitude-4 study are likely to boost investor confidence in Johnson & Johnson's oncology portfolio, potentially driving the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100